A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining

Investigational New Drugs

Volumn 29, Issue 1, 2011, Pages 167-174

  Wierzbicki, Rafal ^f   Jonker, Derek J ^a   Moore, Malcolm J ^b   Berry, Scott R ^c   Loehrer, Patrick J ^d   Youssoufian, Hagop ^e   Rowinsky, Eric K ^e  

^a UNIVERSITY OF OTTAWA   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^d INDIANA UNIVERSITY   (United States)

^e ELI LILLY AND COMPANY   (United States)

^f NONE

Author keywords

Cetuximab; Epidermal growth factor receptor (EGFR); Immunohistochemistry (IHC); Immunostaining; Metastatic colorectal cancer (mCRC)

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN;

ACNE; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANAPHYLAXIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; COLORECTAL CARCINOMA; DERMATITIS; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOXIA; IMMUNOHISTOCHEMISTRY; INJECTION SITE REACTION; LUNG INFILTRATE; LYMPHOCYTOPENIA; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; ONCOGENE K RAS; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RESPIRATORY FAILURE; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; SURVIVAL RATE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TIME FACTORS; TREATMENT OUTCOME;

EID: 79151473575     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-009-9341-6     Document Type: Article

References (25)

1. DS Salomon R Brandt F Ciardiello N Normanno 1995 Epidermal growth factor related peptides and their receptors in human malignancies Crit Rev Oncol Hematol 19 183 232 1:STN:280:DyaK2Mzjs1KgsQ%3D%3D 10.1016/1040-8428(94)00144-I 7612182
2. JA McKay LJ Murray S Curran VG Ross C Clark GI Murray J Cassidy HL McLeod 2002 Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases Eur J Cancer 38 2258 2264 1:STN:280: DC%2BD38notVyquw%3D%3D 10.1016/S0959-8049(02)00234-4 12441262
3. Mendelsohn J, Kawamoto T, Sato G, Sato J. Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor. United States Patent #4,943,533. July 24, 1990
4. NI Goldstein M Prewett K Zuklys P Rockwell J Mendelsohn 1995 Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model Clin Cancer Res 1 1311 1318 1:CAS:528: DyaK28XjvF2gsA%3D%3D 9815926
5. HW Waksal 1999 Role of an anti-epidermal growth factor receptor in treating cancer Cancer Metastasis Rev 18 427 436 1:CAS:528:DC%2BD3cXksFSqsL8%3D 10.1023/A:1006302101468 10855786
6. GP Adams LM Weiner 2005 Monoclonal antibody therapy of cancer Nat Biotechnol 23 1147 1157 1:CAS:528:DC%2BD2MXpvVyrtr0%3D 10.1038/nbt1137 16151408
7. HJ Lenz E Van Cutsem S Khambata-Ford, et al. 2006 Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines J Clin Oncol 24 4914 4921 1:CAS:528:DC%2BD28Xht1eiu73K 10.1200/JCO.2006.06.7595 17050875
8. D Cunningham Y Humblet S Siena, et al. 2004 Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 337 345 1:CAS:528:DC%2BD2cXlvFGitbk%3D 10.1056/NEJMoa033025 15269313
9. DJ Jonker CJ O'Callaghan CS Karapetis 2007 Cetuximab for the treatment of colorectal cancer N Engl J Med 357 2040 2048 1:CAS:528:DC%2BD2sXhtlWis7rI 10.1056/NEJMoa071834 18003960
10. Erbitux [package insert] (2008) ImClone Systems, Branchburg
11. DC Spaulding BO Spaulding 2002 Epidermal growth factor receptor expression and measurement in solid tumors Seminars Oncol 29 45 54 1:CAS:528:DC%2BD38XoslWiuro%3D
12. M Scartozzi I Bearzi R Berardi A Mandolesi G Fabris S Cascinu 2004 Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies J Clin Oncol 22 4772 4778 1:CAS:528:DC%2BD2MXhtFOj 10.1200/JCO.2004.00.117 15570078
13. D Atkins K-A Reiffen C Tegtmeier H Winther MS Bonato S Störkel 2004 Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections J Histochem Cytochem 52 893 901 1:CAS:528:DC%2BD2cXls1alurk%3D 10.1369/jhc.3A6195.2004 15208356
14. AP Dei Tos I Ellis 2005 Assessing epidermal growth factor receptor expression in tumours: What is the value of current test methods Eur J Cancer 41 1383 1392 1:STN:280:DC%2BD2MzhsFKlug%3D%3D 10.1016/j.ejca.2005.03.018 15919198
15. M Hebbar AS Wacrenier C Desauw O Romano S Cattan JP Triboulet FR Pruvot 2006 Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer Anticancer Drugs 17 855 857 1:CAS:528:DC%2BD28XotlOiu7c%3D 10.1097/01.cad. 0000217425.44584.9f 16926635
16. L Saltz N Meropol PJ Loehrer Sr MN Needle J Kopit RJ Mayer 2004 Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor J Clin Oncol 22 1201 1208 1:CAS:528:DC%2BD2cXpsVGktLw%3D 10.1200/JCO.2004.10.182 14993230
17. KY Chung J Shia NE Kemeny, et al. 2005 Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry J Clin Oncol 23 1803 1810 1:CAS:528:DC%2BD2MXjt1Ckuro%3D 10.1200/JCO.2005.08.037 15677699
18. CS Karapetis S Khambata-Ford DJ Jonker, et al. 2008 K-ras mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 359 1757 1765 1:CAS:528:DC%2BD1cXht12nu77J 10.1056/NEJMoa0804385 18946061
19. E Van Cutsem C-H Köhne E Hitre, et al. 2009 Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 1408 1417 10.1056/NEJMoa0805019 19339720
20. C Bokemeyer I Bondarenko A Makhson, et al. 2008 Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 27 663 671 10.1200/JCO.2008.20.8397 19114683
21. World Health Organization (1979) WHO handbook of reporting results of cancer treatment. WHO Publications Centre USA, Albany, pp 1-45
22. EL Kaplan P Meier 1958 Nonparametric estimation from incomplete observations J Am Stat Assoc 53 457 481 10.2307/2281868
23. NS Goldstein M Armin 2001 Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer stage IV colon adenocarcinoma: implications for a standardized scoring system Cancer 92 1331 1346 1:STN:280:DC%2BD3Mritl2nsg%3D%3D 10.1002/1097- 0142(20010901)92:5<1331::AID-CNCR1455>3.0.CO;2-M 11571750
24. EJ Adams JA Green AH Clark JH Youngson 1999 Comparison of different scoring systems for immunohistochemical staining J Clin Pathol 52 75 77 1:STN:280:DyaK1M3nsFSrtA%3D%3D 10.1136/jcp.52.1.75 10343618
25. JP Kallio P Hirvikoski H Helin P Kellokumpu-Lehtinen T Luukkaala TL Tammela PM Martikainen 2003 Membranous location of EGFR is associated with good prognosis in renal cell carcinoma Br J Cancer 89 1266 1269 1:CAS:528: DC%2BD3sXns1Cmurs%3D 10.1038/sj.bjc.6601241 14520458